Sign In
Buy RFL
$2.26
+0.0300 (+1.35%)
At Close: Jul 13, 2026
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
09:00am, Tuesday, 10'th Nov 2020
CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced tod
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
09:30am, Thursday, 29'th Oct 2020
Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma, in the coming months Company to launch clinical trial in clear cell sarcoma, a subtype of soft tissue sarcoma,
